Search

everythinglearnresearchcommunity

for

Search:↓

Prostate cancer cells can make their own androgens to activate the androgen receptor, and treatments like abiraterone may increase this ability, suggesting new therapies should target the entire steroid-making pathway.

Steroidogenesis inhibitors change but don't stop androgen production in prostate cancer.

Certain genetic variants increase the risk of resistance to hormone therapy in prostate cancer patients.

Low-dose DMSO may help treat castration-resistant prostate cancer by reducing key cancer cell receptors.

New treatments targeting androgen receptors show promise for drug-resistant prostate cancer.

The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.

Hormones affect prostate health and disease, with certain hormone imbalances linked to prostate cancer and benign prostatic hyperplasia.

A new method accurately measures nine specific hormones in human blood.

Certain HSD3B1 gene types are linked to worse prostate cancer outcomes and affect treatment response and other health conditions.

New treatments for prostate cancer are less toxic and show promise, but more research is needed to enhance their effectiveness and reduce side effects.

Don't combine abiraterone and spironolactone for prostate cancer treatment as it may worsen the disease.

Certain drugs that block specific enzymes can help treat prostate diseases.

Continued research and awareness are needed to improve treatments for androgen-dependent diseases.

SLCO genes may predict prostate cancer mortality risk, and lifestyle changes improve health in advanced prostate cancer.

The document explains how certain drugs block hormones to treat cancers like breast and prostate cancer.

Therapies targeting the androgen receptor are being developed to treat prostate cancer and improve bone and muscle health.

New drugs and therapies targeting specific pathways show promise in treating advanced prostate cancer.

Natural products can help overcome cancer drug resistance.

Testosterone and finasteride raise insulin and zinc, lower chromium in male rats.

AKR1C3 could be a treatment target for metabolic issues in PCOS.

Some natural compounds may help overcome drug resistance in certain cancers, but more research is needed.

Too much AKR1C3 enzyme causes resistance to finasteride by increasing testosterone.

Most E. coli in broiler chickens are resistant to multiple antibiotics.

New mutations in the VDR gene cause vitamin D-resistant rickets without hair loss.

Early diagnosis and treatment of PCOS is crucial to reduce emotional distress and health risks.

Female mice with disrupted 5α-reductase 1 had significant metabolic issues, including stress response problems, insulin resistance, liver fat buildup, and obesity.

Testosterone may slow down wound healing and increase inflammation.

Low testosterone and 5α-reductase inhibitors can harm men's metabolic and sexual health; testosterone therapy may help, but discussing 5α-RIs' side effects is important.

Finasteride-treated male rats' offspring had altered glucose metabolism, potentially increasing diabetes risk.

Balding and low testosterone increase risk of urinary stones.